



AF 1/16/02

PATENT APPLICATION

TECH CENTER 1600/2909

JAN 16 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: Kaesemeyer Group Art Unit: 1617
Serial No.: 09/419,517 Examiner: Jones, Dwayne
Filing Date: October 18, 1999 Docket No.: 25795-4-2

Title: METHOD AND FORMULATION FOR TREATING VASCULAR DISEASE

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8*


I hereby certify that the below-identified papers are being deposited with the United States Postal Service with sufficient postage as "FIRST CLASS MAIL" on October 25, 2001 in an envelope addressed to: Box AF, Commissioner for Patents, Washington, D.C. 20231

Raymond A. Miller
(type or print name of person mailing paper)

Antoinette Macon
Signature of person mailing paper

Items enclosed herewith:

1. Response to Final Office Action
2. Request for Continued Examination
3. Return Receipt Postcard



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

TECH CENTER 1600/2900

JAN 16 2001

RECEIVED

Applicant: Kaesemeyer

Examiner: Dwayne C. Jones

Serial No.: 09/419517

Art Unit: 1617

Filing Date: October 18, 1999

Docket No: 25795-4-2

Title: METHOD AND FORMULATION FOR TREATING VASCULAR DISEASE

Box AF
Commissioner for Patents
Washington, DC 20231

#12
A. Harmon

8/21/01

**RESPONSE TO FINAL OFFICE ACTION &
REQUEST FOR CONTINUED EXAMINATION**

Dear Sir:

18/21/2002 RHARMON 00000001 022051 09419517

01 FC:179 740.00 CH

REMARKS

Initially, Applicant's attorney wishes to thank Examiner Kim for the careful consideration given this case and the interview conducted with the undersigned on July 17, 2001. After a discussion of the case history during the interview, both Examiner Kim and supervising examiner, Examiner Criares suggested that the present application be refiled as a Request for Continued Examination (RCE), directed to Examiner Dwayne C. Jones, due to his knowledge expertise, and previous experience in related cases (e.g. the parent case - U.S. Patent No. 5,968,983 (the "'983 patent")).

Accordingly, in an effort to accelerate prosecution, and more finitely define the issues, Applicant's attorney is filing herewith an RCE directed to Examiner Dwayne C. Jones. To facilitate review of this case, the claims allowed in the parent case and the pending claims are presented in side by side format. For brevity and ease of comparison, the list of inhibitors of Hmg-CoA reductase specifically recited in Markush format in the '983 patent are identified with the term "Markush Group" in the comparison chart. If the claims of the respective case are identical, this is identified in the chart, and the language is not repeated.

BEST AVAILABLE COPY